Date: 2014-01-23
Type of information: Private placement
Company: Genmab (Denmark)
Investors: selected institutional investors
Amount: DKK 998 million (€ 133.7 million)
Funding type: private placement
Planned used: Potential uses for the net proceeds from the transaction may include, among other things, and without limiting Genmab\'s discretion, the funding of: - Clinical development of HuMax®-TF-ADC (currently in a Phase I study in eight solid tumors) - Progressing Genmab\'s pipeline of pre-clinical projects towards clinical development - Further development of Genmab\'s proprietary technologies, the DuoBody® platform and HexaBody™ platform - Potential complimentary acquisitions of new products, technologies or businesses that would further expand Genmab\'s capabilities and product portfolio - General corporate purposes to support the development of Genmab\'s pipeline and business
Others: * On January 29, 2014, Genmab has announced that the capital increase from the private placement has now been registered with the Danish Business Authority. Following the capital increase, Genmab has a registered nominal share capital of DKK 56,355,722 divided into 56,355,722 shares of DKK 1 each.
* On January 24, 2014, Genmab has announced it has raised gross proceeds of DKK 998 million (€ 133.7 million) following pricing of its previously announced private placement. Genmab will issue 4,600,000 new shares with a nominal value of DKK 1 each at a price of DKK 217 per share. The new shares to be issued as a result of the private placement represent approx. 8.9 % of Genmab\'s registered share capital before the capital increase.
Following the capital increase, Genmab will have a registered nominal share capital of DKK 56,355,722 divided into 56,355,722 shares of DKK 1 each. Registration of the capital increase with the Danish Business Authority is expected to take place on January 29, 2014. The settlement date, on which the new shares will be delivered to the investors against payment, is expected to be January 29, 2014. The settlement is subject to customary closing conditions. Expected date of admission for trading and official listing of the new shares is January 30, 2014. The new shares will be admitted to trading and official listing under the existing ISIN securities identification code for Genmab\'s shares.
In the placing agreement, Genmab has agreed to a 180-day lock-up period on future share issuances, subject to waiver by the global coordinator and to customary exceptions, including for shares issued in connection with licensing, collaboration or acquisition transactions that are locked up for the remainder of the 180-day period.
Therapeutic area: Cancer - Oncology
